No Prescription |
 |
 | ||
|
Voveran SR Voltaren SR |
|
| ||
No Prescription » Prescription Drugs 17 » Voveran SR Voltaren SR Diclofenac is used to relieve pain swelling (inflammation) and joint stiffness caused by arthritis. Reducing these symptoms helps you do more of your normal daily activities. This medication is known as a nonsteroidal anti-inflammatory drug (NSAID). This long-acting medication is not intended to relieve sudden severe pain because it starts working slowly. Buy Voveran SR Voltaren SR and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Voveran SR Voltaren SR: Product Type: Prescription Drugs 17 Voveran SR (Voltaren SR Voltaren XR Generic Diclofenac) Voveran SR (Voltaren SR Voltaren XR Generic Diclofenac) Voltaren SR Voltaren XR Generic Diclofenac 75mg Voltaren SR Voltaren XR Generic Diclofenac Voveran SR
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
